1. Home
  2. GNPX vs PFSA Comparison

GNPX vs PFSA Comparison

Compare GNPX & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.35

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

PFSA

Profusa Inc.

HOLD

Current Price

$1.21

Market Cap

3.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
PFSA
Founded
2009
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.7M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
GNPX
PFSA
Price
$1.35
$1.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
272.2K
6.0M
Earning Date
05-11-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.05
52 Week High
$12.97
$4.22

Technical Indicators

Market Signals
Indicator
GNPX
PFSA
Relative Strength Index (RSI) 25.92 56.83
Support Level $0.18 $0.24
Resistance Level $2.12 $2.22
Average True Range (ATR) 0.12 0.17
MACD -0.05 0.10
Stochastic Oscillator 6.57 43.20

Price Performance

Historical Comparison
GNPX
PFSA

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Share on Social Networks: